516 related articles for article (PubMed ID: 20381863)
21. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
22. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
[TBL] [Abstract][Full Text] [Related]
23. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
[TBL] [Abstract][Full Text] [Related]
24. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
Bernal T; Moncada-Pazos A; Soria-Valles C; Gutiérrez-Fernández A
Exp Hematol; 2013 Feb; 41(2):172-9. PubMed ID: 23085464
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
[TBL] [Abstract][Full Text] [Related]
26. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Krishnadas DK; Bao L; Bai F; Chencheri SC; Lucas K
Tumour Biol; 2014 Jun; 35(6):5753-62. PubMed ID: 24584817
[TBL] [Abstract][Full Text] [Related]
27. Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation.
Park JH; Song MH; Lee CH; Lee MK; Park YM; Old L; Lee SY
Biotechnol Lett; 2011 Jun; 33(6):1085-91. PubMed ID: 21318630
[TBL] [Abstract][Full Text] [Related]
28. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
Wang XY; Chen HS; Luo S; Zhang HH; Fei R; Cai J
Oncol Rep; 2009 Mar; 21(3):713-9. PubMed ID: 19212631
[TBL] [Abstract][Full Text] [Related]
29. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
30. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
[TBL] [Abstract][Full Text] [Related]
31. Expression of BAGE, GAGE, and MAGE genes in human gastric carcinoma.
Li J; Yang Y; Fujie T; Baba K; Ueo H; Mori M; Akiyoshi T
Clin Cancer Res; 1996 Sep; 2(9):1619-25. PubMed ID: 9816341
[TBL] [Abstract][Full Text] [Related]
32. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
[TBL] [Abstract][Full Text] [Related]
33. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
34. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
[TBL] [Abstract][Full Text] [Related]
35. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
[TBL] [Abstract][Full Text] [Related]
36. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
37. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.
Karpf AR; Lasek AW; Ririe TO; Hanks AN; Grossman D; Jones DA
Mol Pharmacol; 2004 Jan; 65(1):18-27. PubMed ID: 14722233
[TBL] [Abstract][Full Text] [Related]
38. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
Weiser TS; Guo ZS; Ohnmacht GA; Parkhurst ML; Tong-On P; Marincola FM; Fischette MR; Yu X; Chen GA; Hong JA; Stewart JH; Nguyen DM; Rosenberg SA; Schrump DS
J Immunother; 2001; 24(2):151-61. PubMed ID: 11265773
[TBL] [Abstract][Full Text] [Related]
39. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
[TBL] [Abstract][Full Text] [Related]
40. Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
Leung KK; Nguyen A; Shi T; Tang L; Ni X; Escoubet L; MacBeth KJ; DiMartino J; Wells JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):695-700. PubMed ID: 30584089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
